Nektar Therapeutics NKTR has entered into a non-exclusive license and clinical trial collaboration with privately-held ImaginAb Inc. to support its immuno-oncology pipeline. The deal will allow Nektar to use ImaginAb's CD8 ImmunoPET technology, which measures the density and distribution of tumor CD8+ T cells in cancer patients.